Previous Article | Next Article 
Journal of Virology, April 2001, p. 3444-3452, Vol. 75, No. 7
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.7.3444-3452.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Inhibition of Histone Deacetylation Induces
Constitutive Derepression of the Beta Interferon Promoter and
Confers Antiviral Activity
Elena
Shestakova,
Marie-Thérèse
Bandu,
Janine
Doly, and
Eliette
Bonnefoy*
Laboratoire de Régulation de la
Transcription et Maladies Génétiques, CNRS, UPR2228, UFR
Biomédicale, Université René Descartes, 75270 Paris Cedex 06, France
Received 1 November 2000/Accepted 3 January 2001
 |
ABSTRACT |
The induction of alpha/beta interferon (IFN-
/
) genes
constitutes one of the first responses of the cell to virus infection. The IFN-
gene is constitutively repressed in uninfected cells and is
transiently activated after virus infection. In this work we
demonstrate that histone deacetylation regulates the silent state of
the murine IFN-
gene. Using chromatin immunoprecipitation (ChIP)
assays, we show a direct in vivo correlation between the transcriptionally silent state and a state of hypoacetylation of
histone H4 on the IFN-
promoter region. Trichostatin A (TSA), a
specific inhibitor of histone deacetylases, induced strong, constitutive derepression of the murine IFN-
promoter stably integrated into a chromatin context, as well as the hyperacetylation of
histone H4, without requiring de novo protein synthesis. We also show
in this work that TSA treatment strongly enhances the endogenous IFN
level and confers an antiviral state to murine fibroblastic L929 cells.
Inhibition of histone deacetylation with TSA protected the cells
against the lost of viability induced by vesicular stomatitis virus
(VSV) and inhibited VSV multiplication. Using antibodies neutralizing
IFN-
/
, we show that the antiviral state induced by TSA is due to
TSA-induced IFN production. The demonstration of the predominant role
of histone deacetylation during the regulation of the constitutive
repressed state of the IFN-
promoter constitutes an interesting
advance on the understanding of the negative regulation of this gene
and opens up the possibility of new therapeutic perspectives.
 |
INTRODUCTION |
The beta interferon (IFN-
) gene
remains silent throughout the cell cycle of a differentiated cell
unless it is activated in response to specific extracellular signals
such as virus infection (10, 11). This activation is only
transitory and is rapidly turned off after virus infection (27,
58). Abundant data have been published concerning the
organization of the minimal promoter region required for the
virus-induced transcriptional activation of this gene (reviewed in
reference 28). This region, which constitutes the
virus-responsive element (VRE), is present between positions
110 and
55 of the promoter and consists of a complex enhancer comprising
DNA-binding sites for several transcription factors such as NF-
B,
proteins belonging to the family of IFN regulatory factors (IRFs), and
activating transcription factor 2 (ATF-2/c-Jun) (29, 57).
The architectural protein high-mobility group protein I (HMGI) binds to
the VRE region of the human IFN-
promoter (28) but not
to the VRE of the murine promoter (4). More recently, it
has been demonstrated that the promoter recruits the transcriptional
coactivator CBP/p300, which carries a histone acetyltransferase
activity (40), after virus infection through interactions
with the transcription factor IRF3 (23, 30, 62). In
contrast to the positive regulation of the gene, the molecular mechanisms leading to the constitutive negative regulation of the
IFN-
gene remain less well understood. It has been known for many
years that the IFN-
gene is under negative control
(12). Two regions of the IFN-
promoter, named negative
regulatory domains (NRD) I and II, have been described as intervening
during the establishment of the constitutive repressed state of the
promoter (12, 13, 39, 63). The NF-
B-repressing factor
(38, 39) and protein PRDI-BF1 (21, 47)
interact with the NRD I region (situated between positions
37 and
60). Interaction of the NF-
B-repressing factor with the NRD I
region prevents the binding of the small amount of NF-
B present in
the nucleus before virus infection and, by doing so, partially
regulates the repressed state of the IFN-
gene. Protein PRDI-BF1 is
a postinduction repressor of the IFN-
gene in conjunction with
members of the Groucho family (45). Its mRNA is detectable
4 h after virus infection, and only very small amounts of the protein
are present before virus infection (21), making this
protein a poor candidate for the establishment of the prolonged
constitutive silencing of the gene (45). The determination
in vivo of virus-induced DNase I-hypersensitive sites (64)
on the NRD II region (situated approximately between positions
110
and
220), as well as the description of a preferential in vitro
interaction of linker histone H1 with this highly A/+T-rich DNA
sequence (4), suggests the presence of an organized
chromatin structure on this region. In a previous work we have
described a specific binding site for HMGI at position
130 of the
murine promoter, between the VRE and NRD II. Binding of HMGI to this site displaced histone H1 in vitro and affected the promoter
derepression in vivo (4).
Several observations tend to indicate that chromatin and chromatin
remodeling play an important role in regulation of the expression of
the IFN-
gene. First, the activation of the IFN-
promoter
resulting from an overexpression of CBP/p300 requires the histone
acetyltransferase activity of this coactivator (34). Second, virus induction leads to a local hyperacetylation of
histone H3 and H4 (42). Third, we have observed
significant differences between the virus-induced
transcriptional activation of the stably transfected murine
IFN-
promoter upon which chromatin has been fully reconstituted and
the transiently transfected promoters upon which chromatin has only
been poorly and randomly reconstituted (4). Also, we have
observed that displacement of H1 in the presence of distamycin or after
overexpression of scaffold attachment regions leads to a partial
derepression of the promoter (4). Abundant biochemical and
genetic data indicate that histone deacetylation and addition of
histone H1 represses gene expression (2, 6, 26) whereas
acetylation of core histones, together with linker histone deficiency,
is correlated with gene transcriptional activation (16, 19, 37,
52).
In this work, we have analyzed the role of histone deacetylation during
the constitutive silencing of the IFN-
gene. We show that inhibition
of histone deacetylases (HDACs) with trichostatin A (TSA), a specific
inhibitor of HDACs (26, 31, 54), induced strong,
constitutive derepression of the murine IFN-
promoter stably
integrated into a chromatin context, as well as high levels of
endogenous IFN. Using chromatin immunoprecipitation (ChIP) assays, we
demonstrate a direct correlation between the repressed, constitutive
silent state of the promoter and a state of hypoacetylation of histone
H4 on the promoter. We also present data indicating that TSA-induced
activation of the murine IFN-
(muIFN-
) promoter is independent of
de novo protein synthesis and is mediated by the NRD II region of the
promoter. Moreover, treatment of murine fibroblast L929 cells with TSA
at concentrations as low as 12.5 ng/ml conferred an antiviral state.
Using antibodies that neutralize IFN-
/
, we show that the
antiviral state induced by TSA is the consequence of an enhanced,
TSA-induced production of endogenous IFNs.
The results presented in this work indicate that histone deacetylation
is one of the main molecular events which potentiates the constitutive
repressed state of the IFN-
promoter. TSA treatment mimics the
effect of virus infection for the activation of the transcriptional
capacity of the IFN-
promoter and confers an antiviral activity.
Both these facts lead us to consider the possibility of new therapeutic
applications linked to TSA treatment for the establishment of an
antiviral state.
 |
MATERIALS AND METHODS |
Cell lines and culture.
The L929 wt330 and wt110 cell lines
were constructed as previously described (4). Briefly, the
corresponding IFN-
chloramphenicol acetyltransferase (CAT) reporter
plasmids were cotransfected in a 5:1 molar ratio with plasmid pCB6,
carrying resistance to Geneticin, by the calcium phosphate method. The
transfected cells were selected for 3 weeks in Dulbecco's modified
Eagle's medium supplemented with antibiotics, L-glutamine,
nonessential amino acids, and 10% fetal calf serum containing G418
(600 µg/ml; GIBCO). Clones were isolated, propagated, and tested for
virus-induced CAT activity during several passages of the cells. An
average of 10 positives clones were pooled and frozen.
Virus infection and CAT assays.
One day prior to virus
infection, the cells were split among six-well plates (200 000 cells/well) in medium without G418. Virus infection was carried out
with Newcastle disease virus (NDV) as previously described
(8). Mock-infected cells were treated like infected cells,
except that no NDV was added to the medium. The cells were harvested at
different times after NDV infection, and CAT activity was measured as
previously described (8). The results presented in each
figure correspond to an average of at least three independent
experiments. For each experiment, NDV inductions were carried out in duplicate.
TSA treatment.
TSA (Sigma), kept at
20°C at 1.0 mg/ml in
dimethyl sulfoxide, was freshly diluted in culture medium and added to
the cells at a final concentration of 50 ng/ml for 48 h. The TSA
was removed from the medium before virus infection. During cytopathic
effect assays, TSA was added at a final concentration of 12.5 ng/ml for 24 h before vesicular stomatitis virus (VSV) infection. In the experiment in Fig. 1B, cycloheximide was added to the medium at a final
concentration of 100 µg/ml 30 min before the TSA was added.
Chromatin immunoprecipitation.
L929 wt330 cells were fixed
by addition of 1% formaldehyde to the medium for 10 min, scraped, and
collected by centrifugation. The cells were resuspended in 0.1 ml of
lysis buffer (1% sodium dodecyl sulfate [SDS], 10 mM EDTA, 50 mM
Tris-HCl [pH 8.1]) supplemented with 0.5 mM phenylmethylsulfonyl
fluoride, 1 µg of pepstatin A per ml, 1 µg of leupeptin per ml, and
0.5 mg of benzamidine per ml as previously described (5).
Then 0.4 ml of Tris-EDTA (TE) was added, the cells were sonicated 10 times for 10 s, each, the lysates were cleared by centrifugation,
and the concentration of DNA was determined. DNA was precipitated with
ethanol, resuspended in 0.1 ml of TE, and diluted 10-fold in dilution
buffer (0.01% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris HCl [pH
8.1], 150 mM NaCl) as previously described (27).
Chromatin solution was precleared for 45 min at 4°C on protein
A-Sepharose 4B beads preadsorbed with sonicated single-stranded DNA (1 ml of a 50% suspension of protein A-Sepharose 4B beads plus 8 µl of
sonicated single-stranded DNA [10 mg/ml]). Corresponding aliquots of
chromatin solution were then incubated with 1 µl of anti-H4 or
anti-H4Ac antibodies (Chemicon) overnight at 4°C. Immune complexes
were collected on protein A beads preadsorbed with sonicated
single-stranded DNA. Beads were washed sequentially once each in TSE
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.1])
with 150 mM NaCl, TSE with 500 mM NaCl, and buffer A (0.25 LiCl, 1%
Nonidet P-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl [pH 8.1])
and three times in TE and then extracted three times with 1% SDS-0.1 M NaHCO3. Cross-links were reversed by heating at 65°C
for 4 h, and DNA was precipitated with ethanol. Precipitates were
resuspended in 20 µl of TE, digested with proteinase K (50 µg/ml)
for 1 hr at 37°C, extracted with phenol-chloroform (1:1), and ethanol
precipitated. PCR analysis of immunoprecipitated DNA was performed
using oligonucleotide F-40 (specific for the pBLCAT3 vector)
(5'-gTT TTC CCA gTC ACg AC-3') as the 5' primer and
oligonucleotide CAT (specific for the CAT reporter gene) (5'-CCA
TTT TAg CTT CCT TAg CTC-3') as the 3' primer. PCR conditions were
as follows: 1 cycle of 94°C for 1 min, 60°C for 1 min, and 72°C
for 1 min); 1 cycle of 94°C for 1 min; 58°C for 1 min, and 72°C
for 1 min; 1 cycle of 94°C for 1 min, 55°C for 1 min, and 72°C
for 1 min; and 20 cycles of 94°C for 1 min; 53°C for 1 min, and
72°C for 1 min.
Cytopathic effect assays.
Monolayer cultures of L929 cells
in 96-well plates were incubated with TSA at a final concentration of
12.5 ng/ml for 24 h before VSV infection. Before VSV infection,
the medium containing TSA was removed. Viruses were diluted in medium
with serum and added directly to the culture medium. The monolayers
were stained with crystal violet as vital dye 48 h after VSV
infection. Polyclonal anti-IFN antibodies were raised against
IFN-
/
produced in C243 cells after NDV infection. The results in
Fig. 3 and 5 (bottom panel) were quantified using a Titertek Multiskan
instrument with a 595-nm filter. In tables 4 and 5, 100% cell
viability corresponds to the intensity of staining measured in
noninfected cells (multiplicity of infection = 0).
Titration of IFN activity.
IFNs present in the supernatants
of virus-infected L929 cells, previously treated or not with TSA (at a
concentration of 12.5 ng/ml for 24 h before NDV infection) were
titrated using the antiviral activity assay described by Mogensen and
Bandu (33) against an IFN-
reference, which had itself
been standardized against the international reference MRC 69/19.
Immunofluorescence microscopy.
Endogenous IFN was revealed
by indirect immunofluorescent microscopy. Murine L929 cells were plated
in 2 ml of medium in six-well plates on 20- by 20-mm coverslips at a
density of 105 cells/ml. The cells were allowed to attach
to the coverslips for several hours, and then TSA, was added at a final
concentration of 50 ng/ml for 24 h. TSA-untreated and -treated
cells were fixed with 3.7% formaldehyde for 15 min at room
temperature, washed with phosphate-buffered saline (PBS), and
permeabilized with 1% Triton X-100 in PBS. Then the cells were
incubated for 1 h at room temperature with sheep polyclonal
antibodies against mouse IFN-
/
(PBL Biomedical Labs) diluted
200-fold in PBS-5% bovine serum albumin (according to the
manufacturer, this dilution corresponds to a final concentration of
5 × 103 neutralization units/ml). The cells were
washed with PBS-5% bovine serum albumin and incubated for 1 h at room
temperature with secondary donkey anti-sheep antibodies conjugated with
CY3 diluted 100-fold. The cells were observed with a Nikon eclipse E600 microscope.
 |
RESULTS |
Inhibition of histone deacetylation leads to nearly complete
derepression of the constitutive silent state of the muIFN-
promoter.
To assess the role of histone deacetylation during the
establishment of the constitutive silent state of the muIFN-
promoter, we have used TSA, a specific inhibitor of histone
deacetylases, and ChIP assays. Since chromatin is correctly
reconstituted in stably transfected DNA templates but remains
incompletely organized in transiently transfected DNAs (22,
49), the effect of histone deacetylation was investigated on a
stably transfected muIFN-
promoter.
Cells from the murine L929 wt330 cell line, constructed as described in
Materials and Methods, carrying a stably integrated wild-type muIFN-
promoter (from promoter positions
330 to +20) CAT reporter construct
were incubated with 50 ng of TSA per ml for 48 h. The cells were
then collected, and their corresponding CAT activities were compared to
the activities obtained with the cells that have not been incubated
with TSA. In the absence of virus infection, the IFN-
promoter is
constitutively repressed so that noninfected L929 wt330 cells display a
very weak CAT activity, only slightly superior to the background values
of the CAT assays. The TSA-dependent inhibition of HDAC led to a
dramatic derepression of the promoter constitutive activity, inducing a
128-fold activation of its transcriptional capacity (Table
1). The activity displayed by the
promoter under these conditions corresponds to 40% of the maximum CAT
activity reached by the promoter 10 h after virus infection in the
absence of TSA. To investigate the effect of TSA on endogenous IFN
production, we carried out indirect immunofluorescence microscopy using
polyclonal anti-mouse IFN-
/
antibodies. As shown in Fig.
1, treatment of non-infected L929 cells
with TSA induced high levels of endogenous IFN synthesis.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 1.
TSA treatment increases the endogenous IFN level in the
absence of virus infection. Noninfected murine L929 cells were
indirectly labeled with anti-IFN / antibodies. Note very low
level of endogenous IFN in untreated cells and its high level in
TSA-treated cells.
|
|
We also analyzed the effect of TSA on the virus-induced kinetics of
IFN-

promoter activation. For this purpose, L929 wt330
TSA-treated
or untreated cells were virus infected after removal
of TSA from the
medium and collected at different times after
infection and their
corresponding CAT activities were determined.
To analyze the effect of
TSA on the virus-induced CAT activity
independently of the effect of
TSA on the constitutive noninduced
CAT activity, we subtracted the
mock-induced (mi) CAT activity
from the final CAT activity obtained
after virus infection (i).
We called this activity the absolute (i

mi) CAT activity. As
shown in Fig.
2A,
TSA-treated cells displayed faster virus-induced
kinetics of
transcription whereas the maximum transcriptional
capacity
reached by the promoter 10 h after infection was not
affected (Table
1; Fig.
2A).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
TSA treatment induces a strong constitutive derepression
of the IFN- promoter. (A) L929 wt330 cells carrying the stably
transfected wild-type muIFN- promoter (from positions 330 to +20)
fused upstream of a CAT reporter gene were treated with TSA as
described in Materials and Methods. The CAT activities of the cells
treated or not treated with TSA (50 ng/ml) for 48 h were measured
at different times after virus infection, and the corresponding
absolute (i mi) CAT activities were determined. (B) CHX was
added, or not added, to the medium at a final concentration of 10 mg/ml
30 min before adding TSA (50 ng/ml). Six hours after addition of TSA,
the cells were infected with NDV; they were collected 5 h after
infection. (C) The IFN protein in the supernatant of virus-infected,
TSA-treated and -untreated cells was titrated, as described in
Materials and Methods, at different times after virus infection. (D)
L929 wt330 and wt110 cells carrying a stably transfected "short"
muIFN- promoter (from positions 110 to +20) lacking the NRD II
region were virus infected, and the corresponding absolute (i mi) CAT activities were measured at different times after infection.
|
|
In Fig.
2B we compare the capacity of TSA to induce transcriptional
activation of the muIFN-

promoter in the presence or
absence of
cycloheximide, an inhibitor of protein synthesis. Cycloheximide
at a
final concentration of 100 µg/ml was added to the medium
of L929
wt330 cells 30 min before TSA was added. Six hours later
the medium was
removed and the cells were virus infected; they
were collected 5 h
after virus infection. As shown in Fig.
2B,
the presence of
cycloheximide during TSA treatment of the cells
did not interfere with
the capacity of TSA to activate the muIFN-
promoter. The effect of
TSA on the transcriptional capacity of
the muIFN-

promoter is
therefore not a consequence of TSA-induced
de nova protein
synthesis.
To investigate the effect of TSA on the virus-induced kinetics of
activation of the endogenous muIFN-

promoter, we titrated
the IFN
activity present in the supernatant of virus-infected
murine L929
TSA-treated or -untreated cells. As shown in Fig.
2C, the effect of TSA
on the virus-induced kinetics of activation
of the endogenous IFN
promoter is analogous to that observed on
the stably integrated
promoter: an increase of the virus-induced
kinetics of IFN production
with no effect on the maximum IFN activity
measured 10 h after
infection.
The IFN-
constitutive silent state is correlated with a state of
hypoacetylation of histone H4 on the muIFN-
promoter region.
The above results indicate that inhibition of HDACs induces IFN-
promoter derepression. To determine if HDAC activity is directly
responsible for maintaining the promoter on a histone-deacetylated state, we carried out ChIP assays with antibodies directed against either histone H4 or the acetylated forms of histone H4 (H4Ac). L929
wt330 cells were mock or virus infected, lysed, and sonicated and
genomic DNA was immunoprecipitated as described in Materials and
Methods. The amount of immunoprecipitated DNA corresponding to the
muIFN-
promoter region was analyzed by PCR using the primers described in Materials and Method. A titration of input DNA is shown in
Fig. 3A. It illustrates that under the
PCR conditions we used here, the intensity of the amplified IFN-
band is proportional to the amount of input DNA. The results in Fig. 3B
to D were quantified by PhosphorImager analysis, and the ratio of
IFN-
DNA immunoprecipitated with anti-H4Ac to anti-H4
antibodies was determined (Table 2).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Histone H4 on the IFN- promoter region is
hypoacetylated before virus infection in the absence of TSA. DNA from
L929 wt330 cells infected or not infected with NDV and incubated with
or without TSA were immunoprecipitated as described in Materials and
Methods with antibodies raised against H4Ac or nonacetylated H4. The
amount of immunoprecipitated DNA was determined by PCR as described in
Materials and Methods. (A) PCR analysis of increasing amounts of input
DNA: the intensity of the IFN- band obtained after PCR is
proportional to the input of DNA. (B) PCR analysis of DNA from L929
wt330 cells in the absence of TSA ( TSA) immunoprecipitated with H4Ac
or H4 antibodies before and after virus infection. (C) PCR analysis of
DNA from L929 wt330 cells treated with TSA (+TSA) and
immunoprecipitated with H4Ac or H4 antibodies before and after virus
infection. (D) PCR analysis of DNA from L929 wt330 cells, not treated
with TSA, collected 24 h after virus infection, and
immunoprecipitated with H4Ac or H4 antibodies.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Ratio of the PCR-amplified IFN- DNA immunoprecipitated
with anti-H4Ac and anti-H4 antibodies at different times after NDV
infection
|
|
The DNA isolated from constitutively repressed, mock-infected cells was
not immunoprecipitated with antibodies directed against
H4Ac, whereas
it was immunoprecipitated with antibodies raised
against the
nonacetylated form of histone H4 (Fig.
3B). The H4Ac
antibodies we used
can immunoprecipitate the acetylated forms
of any of the four lysine
(Lys5, Lys8, Lys12, and Lys16) of histone
H4. The absence of
immunoprecipitate observed when mock-infected
cells were incubated with
these H4Ac antibodies indicates that
histone H4 on the constitutively
silent promoter is in an unacetylated
state. This observation confirms
our hypothesis that an HDAC is
directly maintaining the muIFN-

promoter in a state of
hypoacetylation.
In Fig.
3C it can be observed that incubation of mock-infected cells
with TSA led to a clear increase in the amount of DNA
immunoprecipitated with H4Ac antibodies. The TSA-induced derepression
of the promoter (in the absence of any virus infection) can therefore
be correlated with an increase in the degree of H4 acetylation
on the
IFN-

promoter region. Concerning the effect of virus infection
on
the degree of histone acetylation on the IFN-

promoter region,
we
have reproduced here with the murine promoter the results previously
obtained by Parekh and Maniatis (
42) with the human
promoter,
i.e., a virus-induced hyperacetylation of histone H4 on the
IFN-
promoter (Fig.
3B).
The IFN-

promoter reaches its maximal activity between 10 and
12 h after virus infection, and then its transcriptional capacity
is turned off. In this work we have investigated if the return
of the
promoter to a silent state could be correlated with a return
of histone
H4 to an unacetylated state. For this purpose we analyzed,
using ChIP
assays, the degree of histone H4 acetylation on the
muIFN-

promoter
region on DNA isolated from L929 wt330 cells
collected 24 h after
infection. The ratio of DNA immunoprecipitated
with H4Ac antibodies as
opposed to H4 antibodies diminished 24
h after infection (Fig.
3D;
Table
2), indicating that histone
deacetylation has occurred during the
postinfection transcriptional
turnoff. Nevertheless, this deacetylation
is only partial, since
24 h after infection the promoter has not
reached the complete
histone hypoacetylated state observed before virus
infection.
Reconstitution of chromatin is linked to DNA replication. It
is
therefore possible that 24 h after infection (i.e., 12 h
after
that the promoter has reached its maximal activity),
reconstitution
of hypoacetylated chromatin has not yet occurred inside
all virus-infected
L929 cells, which divide approximately every 24 h. Nevertheless,
the fact that 24 h after infection, histones on
the promoter region
have not reached the hypoacetylated state observed
before virus
infection suggests that the transcriptional turnoff of the
promoter
does not require the establishment of a complete histone
hypoacetylated
state. Even though some histone deacetylation occurs
during the
postinfection transcriptional turnoff of the promoter, this
is
not the only factor intervening during this phenomenon. As a matter
of fact, factors such as IRF2, PRDI-BF1, and HMGI, not related
to
HDACs, have been previously described as responsible for the
transcriptional turnoff of this
promoter.
HDACs have the capacity to interact with proteins that specifically
bind to methylated DNA (
3), such as protein MeCP2,
which
binds to methylated DNA and exists in a complex with HDAC
(
20,
35). To test the eventual role of DNA methylation during
the
negative regulation of the IFN-

promoter, we carried out
experiments
with the demethylating agent 5-aza-2'-deoxycytidine
(5Aza-dC).
Treatment of the cells with 440 nM 5Aza-dC for 48 h
had no
detectable effect on the transcriptional capacity of the
IFN-

promoter. When we incubated the cells with both TSA and
5Aza-dC, we
obtained the same results as in the presence of TSA
alone (data not
shown). According to these results, DNA methylation
does not seem to be
intervening during the establishment of the
silent state of the IFN-

promoter in conjunction with histone
deacetylation. Besides, no CpG
islands have been identified in
either the 5' or the 3' region of the
muIFN-
locus.
The A/+T-rich NRD II of the IFN-
promoter mediates most of the
effect of TSA.
The upstream A/+T-rich NRD II region of the human
IFN-
promoter has been described as a negative regulatory element
participating in the establishment of the constitutive silent state of
the human IFN-
gene (63). We were therefore interested
in determining if the effect of TSA was mediated by this region. For
this purpose, we constructed a murine L929 wt110 cell line carrying a
stably transfected short muIFN-
promoter (from positions
110 to
+20) fused upstream of a CAT reporter gene. The wt110 promoter, which contains the entire VRE but lacks the NRD II region, displayed a
phenotype analogous to the one induced by TSA on the wild-type wt330
promoter: a high constitutive transcriptional capacity (the CAT
activity was 33,064 ± 12,540 and 86,189 ± 6,819 cpm/h/mg in the absence and presence of 50 ng of TSA/ml, respectively) and rapid
kinetics of induction (Fig. 2D). Deletion of the NRD II region mimics
most of the effects induced by TSA on the muIFN-
promoter.
Interestingly, TSA had only a weak effect on this promoter (2.6-fold
activation), which carries only the VRE region, compared to its effect
observed on the wt330 promoter (128-fold activation), which contains
the VRE and the NRD II region. The effect of TSA appears to be mediated
mainly by the NRD II rather than the VRE region.
TSA treatment confers antiviral activity.
Since TSA treatment
induced IFN-
promoter activation and IFN-
production confers
antiviral activity (10), we decided to investigate if TSA
treatment by itself could induce an antiviral state. For this purpose,
we compared the cytopathic effect of VSV, the capacity of VSV infection
to induce cell death, and the capacity of the virus to multiply on
murine fibroblastic L929 cells previously treated or not treated with TSA.
To avoid secondary effects of TSA on cell viability, the time of
incubation with TSA and the concentration of TSA were reduced
during
these experiments to 12.5 ng/ml for 24 h. After TSA treatment,
the
medium containing TSA was removed and medium containing increasing
virus concentrations was added to TSA-treated or untreated cells.
As
cells were infected with increasing amounts of virus, the proportion
of
viable cells found 48 h later decreased, as evidenced by the
failure to stain with a vital dye. Figure
4 compares the cytopathic
effect of VSV
infection on the TSA-treated and untreated cells.
Vital-dye staining of
the cells was quantified using a Titertek
Multiskan instrument with a
595-nm filter. For the TSA-treated
cells, cell viability was almost
completely lost at a MOI of 0.3,
whereas under TSA-untreated
conditions, cell viability was almost
completely lost at a MOI of
0.0003 (Table
3). TSA treatment rendered
the murine L929 fibroblast cells 1,000-fold more resistant to
VSV
infection than the control untreated cells.

View larger version (88K):
[in this window]
[in a new window]
|
FIG. 4.
TSA treatment induces resistance to VSV infection.
Confluent monolayers of murine L929 cells were incubated in the absence
of TSA (TSA ) or in the presence of 12.5 ng/ml of TSA (TSA+) for
24 h. The medium was then removed, and the cells were infected
with increasing MOI of VSV and subsequently stained with a vital dye
48 h after infection.
|
|
The supernatants from TSA-treated and untreated cells, infected as in
Fig.
4 at a MOI of 0.1, were collected 24 h after infection
and
added, after serial 10-fold dilutions, to the corresponding
wells of
another plate containing L929 cells. As shown in Fig.
5, no cell death was observed after
incubation of the cells with
the conditioned medium from TSA-treated
cells whereas cell death
was observed after addition of the conditioned
medium from untreated
cells, even after dilution of this medium
1,000-fold. This clearly
shows that the virus was able to multiply on
TSA-untreated cells
but not on TSA-treated cells. Two effects can
therefore be directly
linked to TSA treatment of L929 cells: protection
against cell
death induced by VSV infection, and inhibition of VSV
multiplication.
Both these effects are characteristic of an antiviral
activity.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 5.
TSA treatment inhibits VSV multiplication. Supernatant
(diluted 10-, 100-, 1,000-, or 10,000-fold) from TSA-treated (TSA+) or
untreated (TSA ) cells infected with VSV at a MOI of 0.1, as in Fig.
3, was used to infect confluent monolayers of murine L929 cells. The
cells were stained with vital dye 48 h after the medium was
added.
|
|
TSA-induced antiviral activity is a consequence of IFN
production.
To test if the antiviral state observed after TSA
treatment was a consequence of IFN production, we used antibodies
directed against and neutralizing IFN-
/
. Murine
fibroblast L929 cells were incubated with 12.5 ng of TSA
per ml or without TSA for 24 h in the presence or absence of
anti-IFN antibodies. After 24 h, the medium was removed and the
cells were infected with increasing amounts of VSV either in the
presence or in the absence of anti-IFN antibodies. The amount of
antibodies used during TSA treatment as well as during VSV infection
was sufficient to neutralize 15,000 U of IFN-
per ml.
As shown in Fig.
6 (top panel), the
presence of anti-IFN antibodies at this concentration was capable to
abolish the TSA-induced
antiviral state. The resistance of TSA-treated
cells to the VSV
cytopathic effect was completely lost in the
presence of IFN-neutralizing
antibodies. Complete loss of cell
viability occurred at a MOI
of 0.0003 under TSA-treated conditions with
antibody present,
compared to the MOI of 0.3 under TSA-treated
conditions with no
antibody. As
previously described (
43), IFN-neutralizing antibodies
had
essentially no effect on the cytopathic effect of VSV control
cells
(Fig.
6, middle panel). In the presence of IFN-neutralizing
antibodies,
TSA-treated and untreated cells have approximately
the same resistance
to VSV infection (Fig.
6 bottom panel; Table
4), further confirming
that the TSA-induced antiviral state is
due to enhanced, TSA-induced
endogenous IFN production.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 6.
The TSA-induced antiviral state is due to IFN
production. (Top) Murine L929 cells seeded in a 96-well plate were
incubated with TSA (TSA+), as in Fig. 3, in the presence or absence of
antibodies directed against IFN- / (ab's) sufficient to
neutralize a maximum of 15,000 U of IFN- per ml. After 24 h,
the medium was removed and the cells were infected with increasing
amounts of VSV in the presence or absence of anti-IFN antibodies
(ab's) sufficient to neutralize a maximum of 15,000 U of IFN- per
ml and subsequently stained with a vital dye 48 h after infection.
(Middle) Murine L929 cells were incubated with anti-IFN antibodies
(ab's) and VSV infected in the presence of antibodies, as in top
panel, except that no TSA was added to the medium (TSA ). (Bottom)
Murine L929 cells were incubated with (TSA+) or without (TSA ) TSA in
the presence or absence of anti-IFN antibodies (ab's) and VSV infected
as in the top panel.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Percent cell viability obtained in the presence or
absence of TSA and in the presence of anti-IFN / antibodies
|
|
 |
DISCUSSION |
Eukaryotic genomes are assembled into a potentially repressive
chromatin environment (50). The capacity of eukaryotic
organism to maintain some genes in a transcriptionally silent state is essential to successfully carry out key molecular events such as cell
development and differentiation (36, 41, 46, 51, 55), cell
cycle regulation (7, 25, 26, 47), and regulation of the
transient expression of genes which have a very low demand during a
cell cycle, whose temporary activation results from extracellular signals (2, 59). Data from genetic as well as biochemical experiments have established that chromatin condensation plays a major
role during constitutive gene silencing (17, 60, 61). Histone deacetylation alone (2, 18) or coupled with DNA
methylation (35, 44) is important during the maintenance
of the repressed state of temporarily induced genes such as the genes
regulated by ligand-dependent nuclear receptors. IFN genes belong to a
similar class of genes that remain inactive through a cell cycle unless extracellular signals such as viruses or other pathogens temporarily activate them.
In this work we have analyzed the role of histone deacetylation during
the establishment of the constitutive silent state of the IFN-
gene.
Using ChIP assays, we showed that during the constitutive
transcriptionally silent state, histone H4 on the IFN-
promoter is
hypoacetylated. TSA treatment of murine fibroblast L929 wt330
cells, carrying a stably integrated muIFN-
promoter, led to
the constitutive derepression of the muIFN-
promoter as well as to
enhanced kinetics of the virus-induced transcriptional capacity of the
IFN-
promoter. As shown by our ChIP assays, the TSA-induced promoter
derepression was associated with TSA-induced histone H4 acetylation at
the promoter locus. Experiments performed in the presence of
cycloheximide indicated that the effect of TSA on the transcriptional
capacity of the IFN-
was not mediated by a protein induced during
TSA treatment. Immunocytochemistry experiments allowed us to visualize
the enhanced production of endogenous IFN after TSA treatment in the
absence of virus infection. It is interesting that even though the
level of IFN in noninfected, TSA-untreated cells is very low, it is not
completely null. Some IFN seems to be present in noninfected,
TSA-untreated L929 cells. Titration of the IFN activity present in the
supernatant of virus-infected TSA-treated or -untreated cells showed
that TSA treatment affected the virus-induced kinetics of activation of
the endogenous promoter in a manner similar to that observed with the
stably integrated promoter.
Our demonstration of the predominant role of HDAC activity during the
regulation of the constitutive repressed state of the IFN-
promoter
opens new perspectives concerning the understanding of the negative
regulation of this gene. Two families of HDACs have been described in
mammals: the family comprising HDACs 1 to 3, which belong to class I
HDACs and have similarities to yeast transcriptional repressor protein
Rpd3p, and the family comprising HDACs 4 to 6, which belong to class II
HDACs and have similarities to yeast HDA1 deacetylase (15,
32). HDACs do not bind to DNA directly but are recruited to
specific promoters by transcription factors. Quite often they function
in large multiprotein complexes, such as mSin3A, NuRD
(nucleosome-remodeling histone deacetylase), MeCP2, and Mi2 (9,
60). In this work, we present data indicating that the NRD II
region of the muIFN-
promoter mediates most of the effect of TSA and
that deletion of this region mimics the effect of TSA. The NRD II
region behaves as the region responsible for the local recruitment of
HDAC to the IFN-
promoter region, but the factor(s) directly
responsible for this local recruitment remains to be identified.
Since TSA treatment of the cells was able to mimic the effect of virus
infection for the activation of the IFN-
promoter, we next
investigated if TSA treatment could by itself confer an antiviral
activity analogous to the one conferred by IFN-
production. For this
purpose, we measured the cytopathic effect of VSV on murine L929 cells
treated or not treated with TSA. To avoid secondary effects associated
with TSA, we used a much smaller amount of TSA as well as a much
shorter period of TSA treatment in these experiments. Despite these
milder conditions, a 1,000-fold-increased virus resistance was observed
in cells treated with 12.5 ng of TSA per ml for 24 h compared to
that in nontreated cells. The VSV-induced cell death, as well as the
capacity of the virus to multiply on murine fibroblast L929 cells, was
strongly inhibited after incubation of the cells with TSA. Antibodies
neutralizing IFN-
/
completely abolished the antiviral effect of
TSA, demonstrating that the TSA-induced antiviral state is due to an
enhanced TSA-induced IFN production. The effects induced by TSA at
concentrations as low as 12.5 ng/ml open the possibility of interesting
therapeutic applications. Such applications should be encouraged by the
positive therapeutic results that have already been obtained with HDAC inhibitors either in vitro or in vivo (14, 24, 56).
Van Lint et al. have shown that less than 5% of cellular genes have
their expression modified after treatment with TSA (54). It would be interesting to determine if this rather restrained number
of genes include other IFN or IFN-inducible genes. Chromatin remodeling
has been proposed to intervene during the regulation of cytokine gene
expression on T cells (1, 48), and TSA-dependent gene
activation has been observed for the pleitropic cytokine interleukin-6
(53). It is therefore possible that chromatin remodeling
is a regulatory mechanism shared by several cytokine and
cytokine-inducible genes during their transition from a silent to an
active state and back to a silent transcriptional state.
 |
ACKNOWLEDGMENTS |
We are grateful to Suzanne Chousterman for critical reading of
the manuscript and discussions, to Sebastian Navarro for encouragement and fruitful suggestions, and to Eugenio Prieto for photographic work.
This work was supported by the Centre de la Recherche Scientifique
(CNRS) and by grants from the Association pour la Recherche sur le
Cancer (9994) and CNRS PCV program (PCV098-33). E. Shestakova is the
recipient of a CNRS postdoctoral fellowship (until September 2000) and
of a fellowship from the Fondation pour la Recheche Médical (FRM)
(since October 2000).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire de
Régulation de la Transcription et Maladies
Génétiques, CNRS, UPR2228, UFR Biomédicale,
Université René Descartes, 45 rue des Saints-Pères, 75270 Paris Cedex 06, France. Phone: (33) 01.42.86.22.76. Fax: (33)
01.42.86.20.42. E-mail:
bonnefoy{at}biomedicale.univ-paris5.fr.
 |
REFERENCES |
| 1.
|
Agarwal, S., and A. Rao.
1998.
Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation.
Immunity
9:765-775[CrossRef][Medline].
|
| 2.
|
Alland, L.,
R. Muhle,
H. Hou, Jr.,
J. Potes,
L. Chin,
N. Schreiber-Agus, and R. A. DePinho.
1997.
Role for N-Cor and histone deacetylase in Sin3-mediated transcriptional repression.
Nature
387:49-55[CrossRef][Medline].
|
| 3.
|
Bestor, T. H.
1998.
Methylation meets acetylation.
Nature
393:311-312[CrossRef][Medline].
|
| 4.
|
Bonnefoy, E.,
M-T. Bandu, and J. Doly.
1999.
Specific binding of high-mobility-group I (HMGI) protein and histone H1 to the upstream AT-rich region of the murine beta interferon promoter: HMGI protein acts as a potential antirepressor of the promoter.
Mol: Cell. Biol.
19:2803-2816[Abstract/Free Full Text].
|
| 5.
|
Braunstein, M.,
A. B. Rose,
S. G. Holmes,
C. D. Allis, and J. R. Broach.
1993.
Transcriptional silencing in yeast is associated with reduced nucleosome acetylation.
Genes Dev.
7:592-604[Abstract/Free Full Text].
|
| 6.
|
Braunstein, M.,
R. E. Sobel,
C. D. Allis,
B. M. Turner, and J. M. Broach.
1996.
Efficient transcriptional silencing in Saccharomyces cerevisiae requires a heterochromatin histone acetylation pattern.
Mol. Cell. Biol.
16:4349-4356[Abstract].
|
| 7.
|
Brehm, A.,
E. A. Miska,
D. J. McCance,
J. L. Reid,
A. J. Bannister, and T. Kouzarides.
1998.
Retinoblastome protein recruits histone deacetylase to repress transcription.
Nature
391:597-600[CrossRef][Medline].
|
| 8.
|
Civas, A.,
M. Dion,
G. Vodjdani, and J. Doly.
1991.
Repression of the murine interferon alpha 11 gene: identification of negative acting sequences.
Nucleic Acids Res.
19:4497-4502[Abstract/Free Full Text].
|
| 9.
|
Davie, J. R., and V. A. Spencer.
1999.
Control of histone modifications.
J. Cell. Biochem.
32/33:141-148.
|
| 10.
|
DeMayer, E., and J. DeMayer-Guignard.
1988.
Interferons and other regulatory cytokines.
John Wiley and Sons, Inc., New York, N.Y.
|
| 11.
|
Doly, J.,
A. Civas,
S. Navarro, and G. Uze.
1998.
Type I interferons: expression and signalization.
Cell. Mol. Life Sci.
54:1109-1121[CrossRef][Medline].
|
| 12.
|
Goodbourn, S.,
H. Burstein, and T. Maniatis.
1986.
The human -interferon gene enhancer is under negative control.
Cell
45:601-610[CrossRef][Medline].
|
| 13.
|
Goodbourn, S., and T. Maniatis.
1988.
Overlapping positive and negative regulatory domains of the human -interferon gene.
Proc. Natl. Acad. Sci. USA
85:1447-1451[Abstract/Free Full Text].
|
| 14.
|
Grignani, F.,
S. De Matteis,
C. Nervi,
L. Tomasoni,
V. Gelmetti,
M. Cioci,
M. Fanelli,
M. Ruthardt,
F. F. Ferrara,
I. Zamir,
C. Seiser,
F. Grignani,
M. A. Lazar,
S. Minucci, and P. G. Pelicci.
1998.
Fusion proteins of the retinoic acid receptor- recruit histone deacetylase in promyelocytic leukaemia.
Nature
391:815-818[CrossRef][Medline].
|
| 15.
|
Grozinger, C. M.,
C. A. Hassig, and S. L. Schreiber.
1999.
Three proteins define a class of human histone deacetylases related to yeast Hdap1.
Proc. Natl. Acad. Sci. USA
96:4868-4873[Abstract/Free Full Text].
|
| 16.
|
Grunstein, M.
1997.
Histone acetylation in chromatin structure and transcription.
Nature
389:349-352[CrossRef][Medline].
|
| 17.
|
Hartzog, G. A., and F. Winston.
1997.
Nucleosomes and transcription: recent lessons from genetics.
Curr. Opin. Genet. Dev.
7:192-198[CrossRef][Medline].
|
| 18.
|
Heinzel, T.,
R. M. Lavinsky,
T.-M. Mullen,
M. Söderström,
C. D. Laherty,
J. Torchia,
W-M. Yang,
G. Brard,
S. D. Ngo,
J. R. Davie,
E. Seto,
R. N. Eisenman,
D. W. Rose,
C. K. Glass, and M. Rosenfeld.
1997.
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression.
Nature
387:43-48[CrossRef][Medline].
|
| 19.
|
Ikeda, K.,
D. J. Steger,
A. Eberharter, and J. L. Workman.
1999.
Activation domain-specific and general transcription stimulation by native histone acetyltransferase complexes.
Mol. Cell
19:855-863.
|
| 20.
|
Jones, P. L.,
G. J. C. Veenstra,
P. A. Wade,
D. Vermaak,
S. U. Kass,
N. Landsberger,
J. Strouboulis, and A. P. Wolffe.
1998.
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.
Nat. Genet.
19:187-191[CrossRef][Medline].
|
| 21.
|
Keller, A. D., and T. Maniatis.
1991.
Identification and characterization of a novel repressor of -interferon gene expression.
Genes Dev.
5:868-879[Abstract/Free Full Text].
|
| 22.
|
Lee, H.-Y., and T. K. Archer.
1998.
Prolonged glucocorticoid exposure dephosphorylates histone H1 and inactivates the MMTV promoter.
EMBO J.
17:1454-1466[CrossRef][Medline].
|
| 23.
|
Lin, R.,
L. Heylbroeck,
P. M. Pitha, and J. Hiscott.
1998.
Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation.
Mol. Cell. Biol.
18:2986-2996[Abstract/Free Full Text].
|
| 24.
|
Lin, R. J.,
L. Nagy,
S. Inoue,
W. Shao,
W. H. Miller, and R. M. Evans.
1998.
Role of the histone deacetylase complex in acute promyelocytic leukaemia.
Nature
391:811-814[CrossRef][Medline].
|
| 25.
|
Luo, R. X.,
A. A. Postigo, and D. C. Dean.
1998.
Rb interacts with histone deacetylase to repress transcription.
Cell
92:463-473[CrossRef][Medline].
|
| 26.
|
Magnaghi-Jaulin, L.,
R. Groisman,
I. Naguibneva,
P. Robin,
S. Lorain,
J. P. Le Villain,
F. Troalen,
D. Trouche, and A. Harel-Bellan.
1998.
Retinoblastoma protein represses transcription by recruiting a histone deacetylase.
Nature
391:601-604[CrossRef][Medline].
|
| 27.
|
Maniatis, T.,
L. Whittemore,
W., C. Fan,
A. D. Keller,
V. J. Palombella, and D. N. Thanos.
1992.
Positive and negative control of human interferon- gene expression, p. 1193-1220.
In
S. L. McKnight, and K. P. Yamamoto (ed.), Transcriptional regulation. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 28.
|
Maniatis, T.,
J. V. Falvo,
T. H. Kim,
T. K. Kim,
C. H. Lin,
B. S. Parekh, and M. G. Wathelet.
1998.
Structure and function of the interferon-beta enhanceosome.
Cold Spring Harbor Symp. Quant. Biol.
63:609-620[CrossRef][Medline].
|
| 29.
|
Masumi, A.,
I. M. Wang,
B. Lefebvre,
X.-T. Yang,
Y. Nakatami, and K. Ozato.
1999.
The histone acetylase PCAF is a phorbol-ester-inducible coactivator of the IRF family that confers enhanced interferon responsiveness.
Mol. Cell. Biol.
19:1810-1820[Abstract/Free Full Text].
|
| 30.
|
Merika, M.,
A. J. Williams,
G. Chen,
T. Collins, and D. Thanos.
1998.
Recruitment of CBP/p300 by the IFN enhanceosome is required for synergistic activation of transcription.
Mol. Cell
1:277-287[CrossRef][Medline].
|
| 31.
|
Minucci, S.,
V. Horn,
N. Bhattacharyya,
V. Russanova,
V. V. Ogryzko,
L. Gabriele,
B. H. Howard, and K. Ozato.
1997.
A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells.
Proc. Natl. Acad. Sci. USA
94:11295-11300[Abstract/Free Full Text].
|
| 32.
|
Miska, E. A.,
C. Karlsson,
E. Langley,
S. J. Nielsen,
J. Pines, and T. Kouzarides.
1999.
HDAC4 deacetylase associates with and represses the MEF2 transcription factor.
EMBO J.
18:5099-5107[CrossRef][Medline].
|
| 33.
|
Mogensen, K. E., and M.-T. Bandu.
1983.
Kinetic evidence for an activation step following binding of human interferon 2 to the membrane receptors of Daudi cells.
Eur. J. Biochem.
134:355-364[Medline].
|
| 34.
|
Munshi, N.,
M. Merika,
J. Yie,
K. Senger,
G. Chen, and D. Thanos.
1998.
Acetylation of HMGI(Y) by CBP turns off IFN expression by disrupting the enhanceosome.
Mol. Cell
2:457-467[CrossRef][Medline].
|
| 35.
|
Nan, X.,
H.-H. Ng,
C. A. Johnson,
C. D. Laherty,
B. M. Turner,
R. N. Eisenman, and A. Bied.
1998.
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex.
Nature
393:386-389[CrossRef][Medline].
|
| 36.
|
Nemer, M.
1998.
Histone deacetylase mRNA temporarly and spatially regulated in its expression in sea urchin embryos.
Dev. Growth Differ.
40:583-590[CrossRef][Medline].
|
| 37.
|
Nightingale, K. P.,
R. E. Wellinger,
J. M. Sogo, and P. B. Becker.
1998.
Histone acetylation facilitates RNA polymerase II transcription of the Drosophila hsp26 gene in chromatin.
EMBO J.
17:2865-2876[CrossRef][Medline].
|
| 38.
|
Nourbakhsh, M., and H. Hauser.
1993.
Interferon- promoters contain a DNA element that acts as a position-independent silencer on the NF- B site.
EMBO J.
12:451-459[Medline].
|
| 39.
|
Nourbakhsh, M., and H. Hauser.
1999.
Constitutive silencing of IFN- promoter is mediated by NRF (NF- B-repressing factor), a nuclear inhibitor of NF- B.
EMBO J.
18:6415-6425[CrossRef][Medline].
|
| 40.
|
Ogryzko, V. V.,
R. L. Schiltz,
V. Russanova,
B. H. Howard, and Y. Nakatani.
1996.
The transcriptional coactivators p300 and CBP are histone acetyltransferases.
Cell
87:953-959[CrossRef][Medline].
|
| 41.
|
O'Neill, L. P.,
A. M. Keohane,
J. S. Lavender,
V. McCabe,
E. Heard,
P. Avner,
N. Brockdorff, and B. M. Turner.
1999.
A developmental switch in H4 acetylation upstream of Xist plays a role in X chromosome inactivation.
EMBO J.
18:2897-2907[CrossRef][Medline].
|
| 42.
|
Parekh, B. S., and T. Maniatis.
1999.
Virus infection leads to localized hyperacetylation of histones H3 and H4 at the IFN- promoter.
Mol. Cell
3:125-129[CrossRef][Medline].
|
| 43.
|
Pine, R.
1992.
Constitutive expression of an ISGF2/IRF1 transgene leads to interferon-independent activation of interferon-inducible genes and resistance to virus infection.
J. Virol.
66:4470-4478[Abstract/Free Full Text].
|
| 44.
|
Razin, A.
1998.
CpG methylation, chromatin structure and gene silencing a three-way connection.
EMBO J.
17:4905-4908[CrossRef][Medline].
|
| 45.
|
Ren, B.,
K. J. Chee,
T. H. Kim, and T. Maniatis.
1999.
PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins.
Genes Dev.
13:125-137[Abstract/Free Full Text].
|
| 46.
|
Ryan, J.,
A. J. Llinas,
D. A. White,
B. M. Turner, and J. Sommerville.
1999.
Maternal histone deacetylase is accumulated in the nuclei of Xenopus oocytes as protein complexes with potential enzyme activity.
J. Cell Biol.
112:2441-2452.
|
| 47.
|
Sambucetti, L. C.,
D. D. Fischer,
S. Zabludoff,
P. O. Kwon,
H. Chamberlain,
N. Trogani,
H. Xu, and D. Cohen.
1999.
Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects.
J. Biol. Chem.
49:34940-34947.
|
| 48.
|
Shannon, M. F.,
S. R. Himes, and J. Attema.
1998.
A role for the architectural transcription factors HMGI(Y) in cytokine gene transcription in T cells.
Immunol. Cell Biol.
76:461-466[CrossRef][Medline].
|
| 49.
|
Smith, C. L., and G. L. Hager.
1997.
Transcriptional regulation of mammalian genes in vivo. A tale of two templates.
J. Biol. Chem.
272:27493-27496[Free Full Text].
|
| 50.
|
Struhl, K.
1999.
Fundamentally different logic of gene regulation in eukaryotes and prokaryotes.
Cell
98:1-4[CrossRef][Medline].
|
| 51.
|
Thompson, E. M.,
E. Legouv, and J.-P. Renard.
1998.
Mouse embryos do not wait for the MBT:chromatin and RNA polymerase remodeling in genome activation at the onset of development.
Dev. Genet.
22:31-42[CrossRef][Medline].
|
| 52.
|
Ura, K.,
H. Kurumizaka,
S. Dimitrov,
G. Almouzni, and A. P. Wolffe.
1997.
Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression.
EMBO J.
16:2096-2107[CrossRef][Medline].
|
| 53.
|
Vanden Berghe, W.,
K. De Bosscher,
E. Boone,
S. Plaisance, and G. Haegeman.
1999.
The nuclear factor- B engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter.
J. Biol. Chem.
274:32091-32098[Abstract/Free Full Text].
|
| 54.
|
Van Lint, C.,
S. Emiliani, and E. Verdin.
1996.
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.
Gene Expression
5:245-253[Medline].
|
| 55.
|
Vermaak, D., and A. P. Wolffe.
1998.
Chromatin and chromosomal controls in development.
Dev. Genet.
22:1-6[CrossRef][Medline].
|
| 56.
|
Warrell, R. P.,
L.-Z. He,
V. Richon,
E. Calleja, and P. P. Pandolfi.
1998.
Therapeutic targeting of transcriotion in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
J. Natl. Cancer Inst.
90:1621-1625[Abstract/Free Full Text].
|
| 57.
|
Wathelet, M. G.,
C. H. Lin,
B. S. Parekh,
L. V. Ronco,
P. M. Howley, and T. Maniatis.
1998.
Virus infection induces the assembly of coordinately activated transcription factors on the IFN- enhancer in vivo.
Mol. Cell
1:507-518[CrossRef][Medline].
|
| 58.
|
Whittemore, L.-A., and T. Maniatis.
1990.
Postinduction repression of the -interferon gene is mediated through two positive regulatory domains.
Proc. Natl. Acad. Sci. USA
64:1329-1337[CrossRef].
|
| 59.
|
Wolffe, A. P.
1997.
Sinful repression.
Nature
387:16-17[CrossRef][Medline].
|
| 60.
|
Workman, J. L., and R. E. Kingston.
1998.
Alteration of nucleosome structure as a mechanism of transcriptional regulation.
Annu. Rev. Biochem.
67:545-579[CrossRef][Medline].
|
| 61.
|
Wu, C.
1997.
Chromatin remodeling and the control of gene expression.
J. Biol. Chem.
272:28171-28174[Free Full Text].
|
| 62.
|
Yoneyama, M.,
W. Suhara,
Y. Fukuhara,
M. Fukuda,
E. Nishida, and T. Fujita.
1998.
Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300.
EMBO J.
17:1087-1095[CrossRef][Medline].
|
| 63.
|
Zinn, K.,
D. DiMaio, and T. Maniatis.
1983.
Identification of two distinct regulatory regions adjacent to the human -interferon gene.
Cell
34:865-879[CrossRef][Medline].
|
| 64.
|
Zinn, K., and T. Maniatis.
1986.
Detection of factors that interact with the human -interferon regulatory region in vivo by DNAse I footprinting.
Cell
45:611-618[CrossRef][Medline].
|
Journal of Virology, April 2001, p. 3444-3452, Vol. 75, No. 7
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.7.3444-3452.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Alimirah, F., Chen, J., Davis, F. J., Choubey, D.
(2007). IFI16 in Human Prostate Cancer. Mol Cancer Res
5: 251-259
[Abstract]
[Full Text]
-
Mokrani, H., Sharaf el dein, O., Mansuroglu, Z., Bonnefoy, E.
(2006). Binding of YY1 to the Proximal Region of the Murine Beta Interferon Promoter Is Essential To Allow CBP Recruitment and K8H4/K14H3 Acetylation on the Promoter Region after Virus Infection. Mol. Cell. Biol.
26: 8551-8561
[Abstract]
[Full Text]
-
Klar, M., Bode, J.
(2005). Enhanceosome Formation over the Beta Interferon Promoter Underlies a Remote-Control Mechanism Mediated by YY1 and YY2. Mol. Cell. Biol.
25: 10159-10170
[Abstract]
[Full Text]
-
Nakamura, T., Kukita, T., Shobuike, T., Nagata, K., Wu, Z., Ogawa, K., Hotokebuchi, T., Kohashi, O., Kukita, A.
(2005). Inhibition of Histone Deacetylase Suppresses Osteoclastogenesis and Bone Destruction by Inducing IFN-{beta} Production. J. Immunol.
175: 5809-5816
[Abstract]
[Full Text]
-
Shestakova, E. A., Mansuroglu, Z., Mokrani, H., Ghinea, N., Bonnefoy, E.
(2004). Transcription factor YY1 associates with pericentromeric {gamma}-satellite DNA in cycling but not in quiescent (G0) cells. Nucleic Acids Res
32: 4390-4399
[Abstract]
[Full Text]
-
Kim, J.-M., Liu, H., Tazaki, M., Nagata, M., Aoki, F.
(2003). Changes in histone acetylation during mouse oocyte meiosis. JCB
162: 37-46
[Abstract]
[Full Text]
-
Genin, P., Morin, P., Civas, A.
(2003). Impairment of Interferon-Induced IRF-7 Gene Expression due to Inhibition of ISGF3 Formation by Trichostatin A. J. Virol.
77: 7113-7119
[Abstract]
[Full Text]
-
Weill, L., Shestakova, E., Bonnefoy, E.
(2003). Transcription Factor YY1 Binds to the Murine Beta Interferon Promoter and Regulates Its Transcriptional Capacity with a Dual Activator/Repressor Role. J. Virol.
77: 2903-2914
[Abstract]
[Full Text]
-
Island, M.-L., Mesplede, T., Darracq, N., Bandu, M.-T., Christeff, N., Djian, P., Drouin, J., Navarro, S.
(2002). Repression by Homeoprotein Pitx1 of Virus-Induced Interferon A Promoters Is Mediated by Physical Interaction and trans Repression of IRF3 and IRF7. Mol. Cell. Biol.
22: 7120-7133
[Abstract]
[Full Text]
-
Bachmann, A., Hanke, B., Zawatzky, R., Soto, U., van Riggelen, J., zur Hausen, H., Rosl, F.
(2002). Disturbance of Tumor Necrosis Factor Alpha-Mediated Beta Interferon Signaling in Cervical Carcinoma Cells. J. Virol.
76: 280-291
[Abstract]
[Full Text]